Search - tctmd.com

Displaying 1 - 20 of 78

Sort: Relevancy | Date

News Daily News

Surgical Aortic Valve Repair Effective, Durable in Experienced Hands

Caitlin E. Cox

December 21, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

Presenter: Danny Dvir

November 01, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Presenter: Haim Danenberg

November 01, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Presenter: Martin B. Leon

November 01, 2017

Presentation TCT 2017

Commentary I Insights From the 3M Trial

Presenter: David A. Wood

November 01, 2017

Presentation TCT 2017

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Presenter: Omar K. Khalique

November 01, 2017

Presentation TCT 2017

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Presenter: Ganesh Manoharan

November 01, 2017

Presentation TCT 2017

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Presenter: Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

Presenter: Saif Anwaruddin

November 01, 2017

News Conference News TCT 2017

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Yael L. Maxwell

November 01, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

TCT 52: Novel Preclinical Assessment of Transcatheter Mitral Valve Replacement by Micro-Computed Tomography: µCT Imaging-Guided Histopathological Evaluation

Presenter: Peter C. Block, Lars Sondergaard, Armando Tellez, MD

October 31, 2017

Presentation TCT 2017

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

Presenter: Peter C. Block, Lars Sondergaard, Tarun Chakravarty, MD

October 31, 2017

Presentation TCT 2017

TCT 50: Impact of Anticoagulation Therapy on Valve Hemodynamic Deterioration Following Transcatheter Aortic Valve Replacement

Presenter: Peter C. Block, Lars Sondergaard, Maria Del Trigo, MD

October 31, 2017

Presentation TCT 2017

TCT 49: Long-Term Valve Function 5-9 Years After Transcatheter Aortic Valve Implantation: Data From the UK-TAVI Registry. On Behalf of the National Institute for Cardiovascular Outcomes Research (NICOR)

Presenter: Peter C. Block, Lars Sondergaard, Daniel J. Blackman

October 31, 2017

Presentation TCT 2017

Editorial Perspective: Long-term Valve Performance and Durability: The Next Frontier in Catheter-based Valve Technologies

Presenter: Louis A. Cannon, Peter J. Fitzgerald, Juan F. Granada, Susheel K. Kodali

October 31, 2017

Advertisement

Surgical Aortic Valve Repair Effective, Durable in Experienced Hands

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Point A Multi-Device Lesion-Specific Approach is Preferred!

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Commentary I Insights From the 3M Trial

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

TCT 52: Novel Preclinical Assessment of Transcatheter Mitral Valve Replacement by Micro-Computed Tomography: µCT Imaging-Guided Histopathological Evaluation

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

TCT 50: Impact of Anticoagulation Therapy on Valve Hemodynamic Deterioration Following Transcatheter Aortic Valve Replacement

TCT 49: Long-Term Valve Function 5-9 Years After Transcatheter Aortic Valve Implantation: Data From the UK-TAVI Registry. On Behalf of the National Institute for Cardiovascular Outcomes Research (NICOR)

Editorial Perspective: Long-term Valve Performance and Durability: The Next Frontier in Catheter-based Valve Technologies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content